- Your selection
- Clear all
- Biotechnology x
- Popular x
- Global x
1 case(s) found.
Sanofi Pasteur’s newly approved dengue vaccine, Dengvaxia, was unusual in that it was launched in the Philippines and other at-risk countries. By choosing to “flip the model” – launch in an emerging market setting as opposed to developed markets – it had to overcome various obstacles across the value chain, from registration to financing to supply.
-
Reference 6212
-
Published 26 Sep 2016
-
Length 22 page(s)
-
Topic Operations
-
Region Global
-
Industry Biotechnology
Sanofi Pasteur’s newly approved dengue vaccine, Dengvaxia, was unusual in that it was launched in the Philippines and other at-risk countries. By choosing to “flip the model” – launch in an emerging market setting as opposed to developed markets – it had to overcome various obstacles across the value chain, from registration to financing to supply.